ACON Laboratories received Emergency Use Authorization for its SARS-COV-2 IgG/IgM rapid test
On Dec. 17, 2020, ACON Laboratories announced that its SARS-COV-2 IgG/IgM Rapid Test has been authorized for emergency…
-
-
Investigational COVID-19 therapeutics evaluated in large clinical trials
On Dec. 17, 2020, NIAID announced that two randomized, controlled Phase 3 clinical trials had begun evaluating investigational…
-
NIAID study of Coronavirus infection and multisystem inflammatory syndrome in children began
On Dec. 17, 2020, NIAID announced that an observational study had launched to evaluate the short- and long-term…
-
XPhyto completed successful SARS-COV-2 RT-PCR diagnostic testk kit validation
On Dec. 17, 2020, XPhyto Therapeutics and 3a-diagnostics announced the successful validation of their point-of-care SARS-CoV-2 (COVID-19) RT-PCR…
-
NEJM published positive initial Regeneron antibody cocktail results in non-hospitalized patients with COVID-19
On Dec. 17, 2020, Regeneron announced that the New England Journal of Medicine (NEJM) had published initial clinical…
-
Johnson & Johnson announced Its first phase 3 COVID-19 vaccine trial ENSEMBLE was fully enrolled
On Dec. 17, 2020, Johnson & Johnson announced that the large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) of…
-
Biotechnology | COVID-19 | FDA | Vaccine
Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.
On Dec. 17, 2020, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
-
COVID-19 the leading cause of death in the United States
On Dec. 17, 2020, JAMA reported that the daily U.S. mortality rate for COVID-19 deaths was equivalent to…
-
PRA Health Sciences collaborated with PWNHealth and Fulgent Genetics provided at-home COVID-19 test
On Dec. 17, 2020, PRA Health Sciences announced the enhancement of its COVID-19 Monitoring Program with the addition…
-
Quest Diagnostics and The Commons Project delivered access to lab data through the CommonHealth App
On Dec. 17, 2020, Quest Diagnostics and The Commons Project, a non-profit public trust dedicated to building and…
-
NIH observational study of coronavirus infection and multisystem inflammatory syndrome in children began
On Dec. 16, 2020, National Institute of Allergy and Infectious Diseases reported that an observational study had launched…
-
Heat Biologics announced completion of ZVX-60 vaccine cell line for COVID-19
On Dec. 16, 2020, Heat Biologics announced it had completed its gp96-based COVID-19 vaccine cell line, which is…
-
SARS-CoV-2 viral genome sequencing data reported from research using Pacific Biosciences Technology
On Dec. 16, 2020, Pacific Biosciences announced initial findings from the companyﾒs research collaboration with Labcorp that was…
-
BD surpassed 1 billion injection device orders in support of COVID-19 vaccination efforts around the world
On Dec. 16, 2020, BD (Becton, Dickinson) announced that it had received pandemic orders for needles and syringes…
-
Novavax announced agreement with government of New Zealand for 107 million doses of COVID-19 vaccine
On Dec. 16, 2020, Novavax announced an Advance Purchase Agreement with the government of New Zealand for the…
-
Meridian received NIH award for supporting rapid development of Revogeneﾮ molecular test for SARS-CoV-2
On Dec. 16, 2020, Meridian Bioscience announced that it had been awarded funding in the amount of approximately…
-
BioNTech and Fosun Pharma to supply China with mRNA-based COVID-19 vaccine
On Dec. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutical announced an agreement to supply Mainland China with an…
-
FDA issued new authorization for the BinaxNOW COVID-19 Ag Card Home Test
On Dec. 16, 2020, the U.S. Food and Drug Administration issued a new emergency use authorization (EUA) for…
-
Abbott’s BinaxNOW COVID-19 rapid rest received FDA Emergency Use Authorization for at-home rapid test
On Dec. 16, 2020, Abbott announced that the FDA had issued Emergency Use Authorization (EUA) for virtually guided…
-
AXIM Biotechnologies completed successful Covid-19 live virus test and filed amended EUA
On Dec. 15, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based…
-
Abbott received CE Mark for its COVID-19 IgG quantitative antibody blood test
On Dec. 15, 2020, Abbott announced it received had CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin…
-
INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19
On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute,…
-
FDA authorized antigen test as first over-the-counter fully at-home diagnostic test for COVID-19
On Dec. 15, 2020, the FDA granted emergency use authorization (EUA) for the first over-the-counter (OTC) fully at-home…
-
TGen identified gene that could explain disparity in COVID-19 effects
On Dec. 15, 2020, TGen, an affiliate of City of Hope announced that it had identified a specific…
-
Aurinia and Lonza announced exclusive agreement for dedicated Voclosporin manufacturing capacity
On Dec. 15, 2020, Aurinia Pharmaceuticals announced the funding and initiation of an open-label exploratory trial evaluating the…
-
RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
-
Moderna confirmed supply agreement to supply Singapore with mRNA vaccine against COVID-19
On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health…
-
Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine storm
On Dec. 14, 2020, Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of…
-
Antibody study suggested COVID-19 infections underestimated
On Dec. 14, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
-
Data from phase 1/2 study further characterized immune response with lead COVID-19 vaccine candidate
On Dec. 14, 2020, Pfizer and BioNTech announced additional data on neutralizing antibody and T cell responses from…
